Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.

Science Signaling
Taro HitosugiJing Chen

Abstract

The Warburg effect describes a pro-oncogenic metabolism switch such that cancer cells take up more glucose than normal tissue and favor incomplete oxidation of glucose even in the presence of oxygen. To better understand how tyrosine kinase signaling, which is commonly increased in tumors, regulates the Warburg effect, we performed phosphoproteomic studies. We found that oncogenic forms of fibroblast growth factor receptor type 1 inhibit the pyruvate kinase M2 (PKM2) isoform by direct phosphorylation of PKM2 tyrosine residue 105 (Y(105)). This inhibits the formation of active, tetrameric PKM2 by disrupting binding of the PKM2 cofactor fructose-1,6-bisphosphate. Furthermore, we found that phosphorylation of PKM2 Y(105) is common in human cancers. The presence of a PKM2 mutant in which phenylalanine is substituted for Y(105) (Y105F) in cancer cells leads to decreased cell proliferation under hypoxic conditions, increased oxidative phosphorylation with reduced lactate production, and reduced tumor growth in xenografts in nude mice. Our findings suggest that tyrosine phosphorylation regulates PKM2 to provide a metabolic advantage to tumor cells, thereby promoting tumor growth.

References

Apr 10, 1995·International Journal of Cancer. Journal International Du Cancer·F Penault-LlorcaO deLapeyrière
Jun 24, 1996·FEBS Letters·A MatteviG Valentini
Dec 1, 1996·Current Opinion in Structural Biology·A MatteviM Bolognesi
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Sep 28, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jing ChenD Gary Gilliland
Dec 14, 2004·Nature Biotechnology·John RushMichael J Comb
May 24, 2005·Seminars in Cancer Biology·Sybille MazurekErich Eigenbrodt
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jorge Sergio Reis-FilhoAlan Ashworth
Feb 16, 2007·European Journal of Gastroenterology & Hepatology·Yogesh KumarBrian R Davidson
Feb 17, 2007·Current Opinion in Cell Biology·M Christiane Brahimi-HornJacques Pouysségur
Jul 3, 2007·Annals of Surgical Oncology·Harsha R HathurusingheAjith K Siriwardena
Feb 27, 2008·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Nobukazu ShimadaShunsuke Ishii
Mar 14, 2008·Nature·Heather R ChristofkLewis C Cantley
Jun 10, 2008·Cancer Cell·Guido Kroemer, Jacques Pouyssegur

❮ Previous
Next ❯

Citations

Mar 31, 2011·Archivum Immunologiae Et Therapiae Experimentalis·Paweł Piątkiewicz, Anna Czech
Mar 20, 2013·Analytical and Bioanalytical Chemistry·Weidong ZhouEmanuel F Petricoin
Jun 25, 2013·Cancer Letters·Weiwei Yang, Zhimin Lu
Mar 20, 2013·Trends in Endocrinology and Metabolism : TEM·David A Foster
Jan 13, 2012·Cell Death & Disease·C Muñoz-PinedoJ-E Ricci
Mar 9, 2013·Cell Death & Disease·Y ZhaoM Tan
Dec 21, 2011·Cell Research·Isaac HarrisTak Wah Mak
Oct 16, 2012·Nature·Barbara ChanetonEyal Gottlieb
Jun 8, 2012·Nature Medicine·Rushdia Z YusufDavid T Scadden
Apr 18, 2012·Proceedings of the National Academy of Sciences of the United States of America·Jiangbin YeCraig B Thompson
Dec 26, 2012·Proceedings of the National Academy of Sciences of the United States of America·Marta Cortés-CrosFrancesco Hofmann
Mar 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Hugh P MorganMalcolm D Walkinshaw
Mar 5, 2011·The Journal of Biological Chemistry·Takeharu SakamotoMotoharu Seiki
Feb 15, 2012·The Journal of Experimental Medicine·Robert B Hamanaka, Navdeep S Chandel
Nov 3, 2011·Journal of Molecular Cell Biology·Zhenxun WangAdrian R Krainer
Dec 20, 2013·Open Biology·Marlous J Groenewoud, Fried J T Zwartkruis
Sep 18, 2010·Science·Matthew G Vander HeidenLewis C Cantley
Dec 7, 2011·Science·Robert B Hamanaka, Navdeep S Chandel
Aug 28, 2012·Science·Wen YiLinda C Hsieh-Wilson
Oct 12, 2013·Science·Erika L PearceRussell G Jones
Oct 25, 2013·Science Translational Medicine·Gopinath Sutendra, Evangelos D Michelakis
Sep 4, 2013·The Journal of Clinical Investigation·Gregg L Semenza
Jun 9, 2011·Molecular Cancer·Maurice Israël, Laurent Schwartz
Nov 28, 2013·Cancer & Metabolism·Andrew N Macintyre, Jeffrey C Rathmell
Dec 1, 2010·Genome Biology·Shuzhao LiMarius Brouwer
Oct 22, 2010·Molecular Endocrinology·Bentley VargheseSerge Y Fuchs
Jan 12, 2012·PloS One·M Shahriar HossainNaren Ramakrishnan
Jun 10, 2014·PloS One·Bhanu Chandra MulukutlaWei-Shou Hu
Jun 10, 2010·Future Oncology·Ralph J DeBerardinis
Jan 5, 2011·Frontiers in Bioscience (Landmark Edition)·Yuhua ZhaoMing Tan
Sep 17, 2013·Cell Biochemistry and Biophysics·Katarzyna BlochRichard Callaghan
Mar 1, 2014·Nature Reviews. Drug Discovery·Matthias Dobbelstein, Ute Moll

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.